磁性纳米合金晶体在磁共振成像诊断前列腺癌中应用的初步实验研究

Preliminary experimental study of magnetic alloy nanocrystals in prostate cancer diagnosis via magnetic resonance imaging

目的初步探讨镍-钴合金磁性纳米晶体作为对比剂在磁共振成像诊断前列腺癌中的作用。方法采用微波水相法合成出镍-钴合金磁性纳米晶体,使用X射线衍射仪、扫描电子显微镜、透射电子显微镜以及量子扰动超导探测仪对所合成的纳米晶体进行表征和测试,分别获得其相应的理化基本性质及磁学性能。将50μg/ml镍-钴合金磁性纳米晶体在培养板底部有/无磁铁吸附的条件下分别与前列腺癌PC-3、DU-145细胞共培养24h后,洗涤并收集培养板中的PC-3、DU-145细胞,并使用3.0T磁共振成像仪分析镍-钴合金磁性纳米晶体在磁共振成像诊断前列腺癌中的横向弛豫增强效应。结果通过微波水相法合成出了尺寸、形貌均一,并可自组装成环状结构的镍-钴合金磁性纳米晶体,该晶体同时具备铁磁性和可用于磁共振成像的超顺磁性,在外加磁场的作用下,材料可"靶向"聚集于前列腺癌细胞,进而有效缩短磁共振成像诊断前列腺癌的横向弛豫时间。结论初步探讨了镍-钴合金磁性纳米晶体作为新型的磁共振成像对比剂,在前列腺癌的"靶向"诊断中可能发挥的重要作用。

Objective To conduct the preliminary experimental investigation of the role of MRI contrast agents magnetic Ni-Co alloy nanocrystals in prostate cancer diagnosis. Methods Synthesize the magnetic Ni-Co alloy nanocrystals under microwave irradiation in aqueous solution. Then the nanocrystals were characterized by different analytic techniques,such as X-ray powder diffraction, scanning electron microscopy,transmission electron microscopy and superconducting quantum interface de-vice magnetometer measurements,and the basic physico-chemical properties and magnetic behaviors.Incu-bate the prostate cancer cell lines PC-3 and DU-145 with 50μg/ml magnetic Ni-Co alloy nanocrystals,in the presense or absense of a magnet under the cell culture plate for 24 hours.After washing and harvesting the PC-3 and DU-145 cells,the effect of Ni-Co nanoalloys in shortening the T2 relaxation time of MR ima-ging was subsequently evaluated. Results The as-prepared magnetic Ni-Co alloy nanocrystals had uni-form size,shape and can be assembled as nanorings.Besides,the nanoalloys possessed the ferromagnetism and superparamagnetism simultaneously.Under the extra magnetic field,the Ni-Co alloy nanocrystals ac-cumulated at the prostate cancer,and thus the T2 relaxation time of MR imaging could be effectively shortened. Conclusions As a novel kind of MRI contrast agents,magnetic Ni-Co alloy nanocrys-tals might play a certain role on targeted diagnosis of prostate cancer.